$0.8101
0.1115.73%
Last update: Nov 11, 10:57 AM
Metagenomi Therapeutics Inc
MGXNASDAQ
Metagenomi Therapeutics fell 68.2% from $2.20 to $0.70, behind the S&P 500's +9.8%. Its worst day was Nov 12 (−15.5%), and its low came Nov 10 at $0.70.
Nov 11, 2025 – Nov 10, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
EPS of $-0.55 beat the $-0.56 estimate on $8.7M revenue (est. $8.5M).
−15.5%, the year's worst day, on 1M shares, the year's heaviest volume · S&P 500 +0.1%
Story events cover the past 12 months · Times ET
Metagenomi Therapeutics shares rose 9.2%, while the S&P 500 rose 1.9%.
+9.2% · S&P 500 +1.9%
EPS of $-0.60 missed the $-0.58 estimate on $3.9M revenue (est. $7.9M).
−8.1% · S&P 500 −1.3%
EPS of $-0.61 missed the $-0.56 estimate on $1.2M revenue (est. $5.5M).
0.0% · S&P 500 −0.2%
EPS of $-0.73 missed the $-0.54 estimate on $-257,000.00 revenue (est. $3.0M).
−1.6% · S&P 500 −0.3%
Metagenomi Therapeutics shares fell 10.1%, while the S&P 500 fell 0.0%.
−10.1% · S&P 500 0.0%
Where it ended: a close of $0.70 on Nov 10, 2026. Up next: Q3 2026 earnings on Nov 24, 2026 (EPS est. $-0.64, revenue est. $2.1M).
Nothing in the past 12 months.
All MGX dividend historyReplay the year: the line draws itself and stops at each of the 6 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for MGX and SPY from Benzinga historical bars. Not investment advice.
